Smart Chemotherapy Gets Smarter: Advances in Antibody-drug Conjugates
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
The FDA issued 18 oncology-related approvals in Q2 2024 including two first-in-class drugs and a bispecific T-cell engager for...
Learn about cancer vaccines, including the various types used to treat or prevent cancer, and discover what's on the...
The June edition of Editors’ Picks includes a clinical trial that clinched a new FDA approval for adagrasib, a...
Highlights from Cancer Today's summer 2024 issue, including treatment-induced heart conditions, profile of Brian Jones, and more.
Learn about the types of cancer immunotherapy including immune checkpoint inhibitors, ACT, therapeutic vaccines, and more.
LGBTQ+ cancer survivors offer lessons learned, and a researcher explains the odds of chronic conditions in LGBTQ+ survivors.
At a recent AACR Special Conference, experts discussed emerging therapeutic options to overcome resistance to Bacillus Calmette-Guérin (BCG).
Researchers at the AACR Annual Meeting 2024 shared how AACR Project GENIE data is helping their studies.
A recap of the plenary sessions, cutting-edge science, clinical trials, and more covered by the AACR blog.
Researchers around the world are designing and implementing methods to increase access to cancer care in low-resource areas.